Literature DB >> 22835573

Posterior reversible encephalopathy syndrome (PRES): features on CT and MR imaging.

E Hugonnet1, D Da Ines, H Boby, B Claise, V Petitcolin, V Lannareix, J-M Garcier.   

Abstract

Posterior reversible encephalopathy syndrome (PRES) is a rare but severe condition of the central nervous system. It develops in a variety of clinical settings and it has diverse patterns of expression, which can sometimes make diagnosis difficult. Characteristic features are often demonstrated on computed tomography imaging and/or magnetic resonance imaging, meaning that when there is a suspicious clinical picture, this diagnosis should suggest itself. However, clinicians should be aware of some of the less typical features in order to more fully understand this condition, in which early treatment is key to good clinical progress.
Copyright © 2012. Published by Elsevier Masson SAS.

Entities:  

Mesh:

Year:  2012        PMID: 22835573     DOI: 10.1016/j.diii.2012.02.005

Source DB:  PubMed          Journal:  Diagn Interv Imaging        ISSN: 2211-5684            Impact factor:   4.026


  31 in total

Review 1.  Posterior reversible encephalopathy syndrome during the peripartum period: report of four cases and review of the literature.

Authors:  Hasan Buyukaslan; Ugur Lok; Umut Gulacti; Ozgur Sogut; Halil Kaya; Tahir Gokdemir; Oner Yalin
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study.

Authors:  Carlos Kamiya-Matsuoka; Asif M Paker; Linda Chi; Ayda Youssef; Sudhakar Tummala; Monica E Loghin
Journal:  J Neurooncol       Date:  2016-02-22       Impact factor: 4.130

3.  Acute cortical blindness caused by pre-eclampsia in the antepartum; posterior reversible encephalopathy syndrome (PRES).

Authors:  Wang Yacong; Cao Qinying; Zhang Lihong; Zhang Su'e; Shi Liang; Sha Ou
Journal:  Afr Health Sci       Date:  2015-06       Impact factor: 0.927

Review 4.  Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2017-05       Impact factor: 5.606

5.  Recurrent childhood PRES.

Authors:  Fuldem Yildirim Donmez; Ahmet Muhtesem Agildere
Journal:  Neurol Sci       Date:  2015-04-18       Impact factor: 3.307

6.  Transient increase of fractional anisotropy in reversible vasogenic edema.

Authors:  Shihoko Kimura-Ohba; Yi Yang; Jeffrey Thompson; Tomonori Kimura; Victor M Salayandia; Melissa Cosse; Yirong Yang; Laurel O Sillerud; Gary A Rosenberg
Journal:  J Cereb Blood Flow Metab       Date:  2016-02-10       Impact factor: 6.200

7.  MRI Findings in Childhood PRES: What is Different than the Adults?

Authors:  F Y Donmez; P Guleryuz; M Agildere
Journal:  Clin Neuroradiol       Date:  2014-10-08       Impact factor: 3.649

8.  Pressing Issues in COVID-19: Probable Cause to Seize SARS-CoV-2 for Its Preferential Involvement of Posterior Circulation Manifesting as Severe Posterior Reversible Encephalopathy Syndrome and Posterior Strokes.

Authors:  F D'Amore; G Vinacci; E Agosti; L P Cariddi; A V Terrana; F A Vizzari; M Mauri; A Giorgianni
Journal:  AJNR Am J Neuroradiol       Date:  2020-07-30       Impact factor: 3.825

Review 9.  Distinguishing Neuroimaging Features in Patients Presenting with Visual Hallucinations.

Authors:  T T Winton-Brown; A Ting; R Mocellin; M Walterfang; D Velakoulis; F Gaillard
Journal:  AJNR Am J Neuroradiol       Date:  2016-01-07       Impact factor: 3.825

10.  Clinical Utility of Computed Tomography and Magnetic Resonance Imaging for Diagnosis of Posterior Reversible Encephalopathy Syndrome after Stem Cell Transplantation in Children and Adolescents.

Authors:  Christopher E Dandoy; Luke L Linscott; Stella M Davies; James L Leach; Kasiani C Myers; Javier El-Bietar; Ranjit S Chima; Abigail Pate; Adam Nelson; Gregory Wallace; Hector R Wong; Sonata Jodele
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-27       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.